Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 71 articles:
HTML format



Single Articles


    July 2022
  1. YU G, Corn PG, Shen PF, Song JH, et al
    Retinoic acid receptor activation reduces metastatic prostate cancer bone lesions by blocking the endothelial-to-osteoblast transition.
    Cancer Res. 2022 Jul 8. pii: 706930. doi: 10.1158/0008-5472.CAN-22-0170.
    PubMed     Abstract available


  2. DAVIDSON SM, Schmidt DR, Heyman JE, O'Brien JP, et al
    Pyruvate Kinase M1 Suppresses Development and Progression of Prostate Adenocarcinoma.
    Cancer Res. 2022;82:2403-2416.
    PubMed     Abstract available


    June 2022
  3. SHANGGUAN X, Ma Z, Yu M, Ding J, et al
    Squalene epoxidase metabolic dependency is a targetable vulnerability in castration-resistant prostate cancer.
    Cancer Res. 2022 Jun 29. pii: 705311. doi: 10.1158/0008-5472.CAN-21-3822.
    PubMed     Abstract available


  4. BERCHUCK JE, Adib E, Abou Alaiwi S, Dash AK, et al
    The prostate cancer androgen receptor cistrome in African American men associates with upregulation of lipid metabolism and immune response.
    Cancer Res. 2022 Jun 22. pii: 705059. doi: 10.1158/0008-5472.CAN-21-3552.
    PubMed     Abstract available


  5. PATEL R, Ford CA, Rodgers L, Rushworth LK, et al
    Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression.
    Cancer Res. 2022 Jun 8. pii: 704813. doi: 10.1158/0008-5472.CAN-21-1301.
    PubMed     Abstract available


    May 2022
  6. QIN L, Chung YM, Berk M, Naelitz B, et al
    Hypoxia-reoxygenation couples 3betaHSD1 enzyme and cofactor upregulation to facilitate androgen biosynthesis and hormone therapy resistance in prostate cancer.
    Cancer Res. 2022 May 10. pii: 696493. doi: 10.1158/0008-5472.CAN-21-4256.
    PubMed     Abstract available


  7. ABATE-SHEN C, Nunes de Almeida F
    Establishment of the LNCaP Cell Line - The Dawn of an Era for Prostate Cancer Research.
    Cancer Res. 2022;82:1689-1691.
    PubMed     Abstract available


    April 2022
  8. RODRIGUEZ Y, Unno K, Truica MI, Chalmers ZR, et al
    A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer.
    Cancer Res. 2022 Apr 11. pii: 694256. doi: 10.1158/0008-5472.CAN-21-3565.
    PubMed     Abstract available


    March 2022
  9. LI R, Zhu J, Zhong W, Jia Z, et al
    Comprehensive evaluation of machine learning models and gene expression signatures for prostate cancer prognosis using large population cohorts.
    Cancer Res. 2022 Mar 31. pii: 682141. doi: 10.1158/0008-5472.CAN-21-3074.
    PubMed     Abstract available


  10. KARABACAK NM, Zheng Y, Dubash TD, Burr R, et al
    Differential Kinase Activity Across Prostate Tumor Compartments Defines Sensitivity to Target Inhibition.
    Cancer Res. 2022;82:1084-1097.
    PubMed     Abstract available


    February 2022
  11. BOONEN RACM, Wiegant WW, Celosse N, Vroling B, et al
    Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
    Cancer Res. 2022;82:615-631.
    PubMed     Abstract available


  12. IPPOLITO L, Comito G, Parri M, Iozzo M, et al
    Lactate rewires lipid metabolism and sustains a metabolic-epigenetic axis in prostate cancer.
    Cancer Res. 2022 Feb 8. pii: 0008-5472.CAN-21-0914.
    PubMed     Abstract available


  13. MA F, Arai S, Wang K, Calagua C, et al
    Autocrine canonical Wnt signaling primes noncanonical signaling through ROR1 in metastatic castration-resistant prostate cancer.
    Cancer Res. 2022 Feb 7. pii: 0008-5472.CAN-21-1807.
    PubMed     Abstract available


    January 2022
  14. MANDIGO AC, Shafi AA, McCann JJ, Yuan W, et al
    Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer.
    Cancer Res. 2022;82:221-234.
    PubMed     Abstract available


    December 2021
  15. JIANG X, Guo S, Wang S, Zhang Y, et al
    EIF4A3-induced circARHGAP29 promotes aerobic glycolysis in docetaxel-resistant prostate cancer through IGF2BP2/c-Myc/LDHA signaling.
    Cancer Res. 2021 Dec 28. pii: 0008-5472.CAN-21-2988.
    PubMed     Abstract available


  16. XIE W, Reder NP, Koyuncu CF, Leo P, et al
    Prostate cancer risk stratification via non-destructive 3D pathology with deep learning-assisted gland analysis.
    Cancer Res. 2021 Dec 1. pii: 0008-5472.CAN-21-2843.
    PubMed     Abstract available


  17. HAWLEY JR, Zhou S, Arlidge C, Grillo G, et al
    Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors.
    Cancer Res. 2021;81:5833-5848.
    PubMed     Abstract available


    November 2021
  18. JUNG Y, Cackowski FC, Yumoto K, Decker AM, et al
    Correction: CXCL12gamma Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes.
    Cancer Res. 2021;81:5777.
    PubMed    


  19. GIL V, Miranda S, Riisnaes R, Gurel B, et al
    HER3 is an Actionable Target in Advanced Prostate Cancer.
    Cancer Res. 2021 Nov 9. pii: 0008-5472.CAN-21-3360.
    PubMed     Abstract available


  20. GHILDIYAL R, Sawant M, Renganathan A, Mahajan K, et al
    Loss of long non-coding RNA NXTAR in prostate cancer augments androgen receptor expression and enzalutamide resistance.
    Cancer Res. 2021 Nov 5. pii: 0008-5472.CAN-20-3845.
    PubMed     Abstract available


  21. AL-JANABI H, Lewis CE
    Macrophage Regulation of the Development of Castration-Resistant Prostate Cancer.
    Cancer Res. 2021;81:5399-5400.
    PubMed     Abstract available


    October 2021
  22. KUMAR R, Mendonca J, Owoyemi O, Boyapati K, et al
    Supraphysiological testosterone induces ferroptosis and activates immune pathways through nucleophagy in prostate cancer.
    Cancer Res. 2021 Oct 13. pii: 0008-5472.CAN-20-3607.
    PubMed     Abstract available


    August 2021
  23. BUTLER LM, Mah CY, Machiels J, Vincent AD, et al
    Lipidomic profiling of clinical prostate cancer reveals targetable alterations in membrane lipid composition.
    Cancer Res. 2021 Aug 6. pii: 0008-5472.CAN-20-3863.
    PubMed     Abstract available


    July 2021
  24. LABRECQUE MP, Brown LG, Coleman IM, Lakely B, et al
    RNA splicing factors SRRM3 and SRRM4 distinguish molecular phenotypes of castration-resistant neuroendocrine prostate cancer.
    Cancer Res. 2021 Jul 26. pii: 0008-5472.CAN-21-0307.
    PubMed     Abstract available


  25. EL-KENAWI A, Dominguez-Viqueira W, Liu M, Awasthi S, et al
    Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer.
    Cancer Res. 2021 Jul 23. pii: 0008-5472.CAN-20-4028.
    PubMed     Abstract available


  26. MAVURA MY, Huang FW
    How Cancer Risk SNPs May Contribute to Prostate Cancer Disparities.
    Cancer Res. 2021;81:3764-3765.
    PubMed     Abstract available


  27. TAKAYAMA KI, Honma T, Suzuki T, Kondoh Y, et al
    Targeting Epigenetic and Posttranscriptional Gene Regulation by PSF Impairs Hormone Therapy-Refractory Cancer Growth.
    Cancer Res. 2021;81:3495-3508.
    PubMed     Abstract available


  28. STEINER MC, Marston JL, Iniguez LP, Bendall ML, et al
    Locus-Specific Characterization of Human Endogenous Retrovirus Expression in Prostate, Breast, and Colon Cancers.
    Cancer Res. 2021;81:3449-3460.
    PubMed     Abstract available


    June 2021
  29. PALLMANN N, Deng K, Livgard M, Tesikova M, et al
    Stress mediated reprogramming of prostate cancer one-carbon cycle drives disease progression.
    Cancer Res. 2021 Jun 28. pii: 0008-5472.CAN-20-3956.
    PubMed     Abstract available


  30. WEI J, Yin L, Li J, Wang J, et al
    Bidirectional Crosstalk between MAOA and AR Promotes Hormone-Dependent and Castration-Resistant Prostate Cancer.
    Cancer Res. 2021 Jun 24. pii: 0008-5472.CAN-21-0198.
    PubMed     Abstract available


  31. HUANG Z, Tang B, Yang Y, Yang Z, et al
    MAP3K7-IKK inflammatory signaling modulates AR protein degradation and prostate cancer progression.
    Cancer Res. 2021 Jun 22. pii: 0008-5472.CAN-20-4194.
    PubMed     Abstract available


  32. ENRIQUEZ C, Cancila V, Ferri R, Sulsenti R, et al
    Castration-induced down-regulation of SPARC in stromal cells drives neuroendocrine differentiation of prostate cancer.
    Cancer Res. 2021 Jun 21. pii: 0008-5472.CAN-21-0163.
    PubMed     Abstract available


  33. SENA LA, Denmeade SR
    Fatty acid synthesis in prostate cancer: vulnerability or epiphenomenon?
    Cancer Res. 2021 Jun 18. pii: 0008-5472.CAN-21-1392.
    PubMed     Abstract available


    May 2021
  34. OSMULSKI PA, Cunsolo A, Chen M, Qian Y, et al
    Contacts with macrophages promote an aggressive nanomechanical phenotype of circulating tumor cells in prostate cancer.
    Cancer Res. 2021 May 27. pii: 0008-5472.CAN-20-3595.
    PubMed     Abstract available


  35. MATSUSHITA M, Fujita K, Hayashi T, Kayama H, et al
    Gut microbiota-derived short-chain fatty acids promote prostate cancer growth via IGF-1 signaling.
    Cancer Res. 2021 May 26. pii: 0008-5472.CAN-20-4090.
    PubMed     Abstract available


  36. MARTINEZ RS, Salji MJ, Rushworth L, Ntala C, et al
    SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer.
    Cancer Res. 2021 May 13. pii: 0008-5472.CAN-20-3694.
    PubMed     Abstract available


  37. RAHMAN NIA, Sato A, Tsevelnorov K, Shimizu A, et al
    Stomatin-Mediated Inhibition of the Akt Signaling Axis Suppresses Tumor Growth.
    Cancer Res. 2021;81:2318-2331.
    PubMed     Abstract available


  38. LIU Z, Guo C, Das SK, Yu X, et al
    Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy.
    Cancer Res. 2021;81:2429-2441.
    PubMed     Abstract available


    April 2021
  39. MATTHIAS J, Engelhardt J, Schafer M, Bauder-Wust U, et al
    Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies.
    Cancer Res. 2021;81:2234-2245.
    PubMed     Abstract available


  40. LACHANCE J
    Beyond Stamp Collecting: Evolutionary and Functional Genomics Advance Our Understanding of Cancer Biology.
    Cancer Res. 2021;81:1637-1638.
    PubMed     Abstract available


    March 2021
  41. CARRENO DV, Corro NB, Cerda-Infante JF, Echeverria CE, et al
    Dietary Fructose Promotes Prostate Cancer Growth.
    Cancer Res. 2021 Mar 24. pii: 0008-5472.CAN-19-0456.
    PubMed     Abstract available


  42. SHI L, Yan Y, He Y, Yan B, et al
    Mutated SPOP E3 ligase promotes 17betaHSD4 protein degradation to drive androgenesis and prostate cancer progression.
    Cancer Res. 2021 Mar 24. pii: 0008-5472.CAN-20-3258.
    PubMed     Abstract available


  43. WANG J, Wang J, Dai J, Jung Y, et al
    Retraction: A Glycolytic Mechanism Regulating an Angiogenic Switch in Prostate Cancer.
    Cancer Res. 2021;81:1623.
    PubMed    


  44. ZHOU Y, Jin X, Ma J, Ding D, et al
    HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
    Cancer Res. 2021;81:1486-1499.
    PubMed     Abstract available


    February 2021
  45. UNNO K, Chalmers ZR, Pamarthy S, Vatapalli R, et al
    Activated ALK Cooperates with N-Myc via Wnt/beta-catenin Signaling to Induce Neuroendocrine Prostate Cancer.
    Cancer Res. 2021 Feb 26. pii: 0008-5472.CAN-20-3351.
    PubMed     Abstract available


  46. XIE J, Rice MA, Chen Z, Cheng Y, et al
    In vivo imaging of methionine aminopeptidase II for prostate cancer risk stratification.
    Cancer Res. 2021 Feb 26. pii: 0008-5472.CAN-20-2969.
    PubMed     Abstract available


  47. HAN D, Owiredu JN, Healy BM, Li M, et al
    Susceptibility-associated genetic variation in NEDD9 contributes to prostate cancer initiation and progression.
    Cancer Res. 2021 Feb 25. pii: 0008-5472.CAN-20-3042.
    PubMed     Abstract available


  48. PASCHALIS A, Welti J, Neeb AJ, Yuan W, et al
    JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.
    Cancer Res. 2021;81:1087-1100.
    PubMed     Abstract available


  49. STROBL MAR, West J, Viossat Y, Damaghi M, et al
    Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy.
    Cancer Res. 2021;81:1135-1147.
    PubMed     Abstract available


  50. CENTENERA MM, Scott JS, Machiels J, Nassar ZD, et al
    ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer.
    Cancer Res. 2021 Feb 5. pii: 0008-5472.CAN-20-2511.
    PubMed     Abstract available


    January 2021
  51. GHOOCHANI A, Hsu EC, Aslan M, Rice MA, et al
    Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer.
    Cancer Res. 2021 Jan 22. pii: 0008-5472.CAN-20-3477.
    PubMed     Abstract available


  52. DHIMOLEA E, de Matos Simoes R, Kansara D, Weng X, et al
    Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.
    Cancer Res. 2021;81:371-383.
    PubMed     Abstract available


  53. SOLEIMANY AP, Kirkpatrick JD, Su S, Dudani JS, et al
    Activatable Zymography Probes Enable In Situ Localization of Protease Dysregulation in Cancer.
    Cancer Res. 2021;81:213-224.
    PubMed     Abstract available


    December 2020
  54. ALPSOY A, Utturkar SM, Carter BC, Dhiman A, et al
    BRD9 is a critical regulator of androgen receptor signaling and prostate cancer progression.
    Cancer Res. 2020 Dec 21. pii: 0008-5472.CAN-20-1417.
    PubMed     Abstract available


  55. HAGIWARA M, Yasumizu Y, Yamashita N, Rajabi H, et al
    MUC1-C ACTIVATES THE BAF (mSWI/SNF) COMPLEX IN PROSTATE CANCER STEM CELLS.
    Cancer Res. 2020 Dec 15. pii: 0008-5472.CAN-20-2588.
    PubMed     Abstract available


  56. EMAMI NC, Cavazos TB, Rashkin SR, Graff RE, et al
    A large-scale association study detects novel rare variants, risk genes, functional elements, and polygenic architecture of prostate cancer susceptibility.
    Cancer Res. 2020 Dec 8. pii: 0008-5472.CAN-20-2635.
    PubMed     Abstract available


  57. GAO L, Zhang W, Zhang J, Liu J, et al
    KIF15-mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer.
    Cancer Res. 2020 Dec 4. pii: 0008-5472.CAN-20-1965.
    PubMed     Abstract available


    November 2020
  58. BOWEN C, Shibata M, Zhang H, Bergren SK, et al
    CRISPR/Cas9-Mediated Point Mutation in Nkx3.1 Prolongs Protein Half-Life and Reverses Effects Nkx3.1 Allelic Loss.
    Cancer Res. 2020;80:4805-4814.
    PubMed     Abstract available


  59. LI G, Kanagasabai T, Lu W, Zou MR, et al
    KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.
    Cancer Res. 2020;80:4633-4643.
    PubMed     Abstract available


    October 2020
  60. SAWANT DESSAI A, Palestino Dominguez M, Chen UI, Hasper J, et al
    Transcriptional repression of SIRT3 potentiates mitochondrial aconitase activation to drive aggressive prostate cancer to the bone.
    Cancer Res. 2020 Oct 28. pii: 0008-5472.CAN-20-1708.
    PubMed     Abstract available


    September 2020
  61. BEKETOVA E, Fang S, Owens JL, Liu S, et al
    Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancer.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-20-1228.
    PubMed     Abstract available


  62. SHAH N, Kesten N, Font-Tello A, Chang MEK, et al
    ERG-mediated coregulator complex formation maintains androgen receptor signaling in prostate cancer.
    Cancer Res. 2020 Sep 15. pii: 0008-5472.CAN-20-2044.
    PubMed     Abstract available


  63. WANG C, Li J
    A deep learning framework identifies pathogenic noncoding somatic mutations from personal prostate cancer genomes.
    Cancer Res. 2020 Sep 9. pii: 0008-5472.CAN-20-1791.
    PubMed     Abstract available


    August 2020
  64. SCHONHOFT JD, Zhao JL, Jendrisak A, Carbone EA, et al
    Morphology-predicted large scale transition number in circulating tumor cells identifies a chromosomal instability biomarker associated with poor outcome in castration-resistant prostate cancer.
    Cancer Res. 2020 Aug 19. pii: 0008-5472.CAN-20-1216.
    PubMed     Abstract available


    June 2020
  65. XU S, Fan L, Jeon HY, Zhang F, et al
    p300-mediated acetylation of histone demethylase JMJD1A prevents its degradation by ubiquitin ligase STUB1 and enhances its activity in prostate cancer.
    Cancer Res. 2020 Jun 10. pii: 0008-5472.CAN-20-0233.
    PubMed     Abstract available


  66. SETTON JS, Powell SN
    Moving beyond PARP Inhibition in ATM-Deficient Prostate Cancer.
    Cancer Res. 2020;80:2085-2086.
    PubMed     Abstract available


    May 2020
  67. LI S, Fong KW, Gritsina G, Zhang A, et al
    Correction: Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer.
    Cancer Res. 2020;80:2072.
    PubMed    


  68. HARLEMON M, Ajayi O, Kachambwa P, Kim MS, et al
    A custom genotyping array reveals population-level heterogeneity for the genetic risks of prostate cancer and other cancers in Africa.
    Cancer Res. 2020 May 11. pii: 0008-5472.CAN-19-2165.
    PubMed     Abstract available


  69. WAHDAN-ALASWAD RS, Song K, Krebs TL, Shola DTN, et al
    Retraction: Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling.
    Cancer Res. 2020;80:1902.
    PubMed    


    April 2020
  70. WU H, You L, Li Y, Zhao Z, et al
    Loss of a negative feedback loop between IRF8 and AR promotes prostate cancer growth and enzalutamide resistance.
    Cancer Res. 2020 Apr 27. pii: 0008-5472.CAN-19-2549.
    PubMed     Abstract available


  71. MAO N, Gao D, Hu W, Gadal S, et al
    Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.
    Cancer Res. 2020;80:1428-1437.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: